Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificates.
The company sources said Bharat Biotech is currently holding discussions with international “potential partners” who have approached the company to manufacture and distribute the intranasal vaccine globally.
“Since iNCOVACC has been approved for “Restricted use under emergency situation” and vaccine recipients will require vaccine certificates, we have requested the government to include iNCOVACC in the COWIN portal. Once this is enabled, India will be one of the few countries to have introduced an intranasal vaccine in its immunization program against COVID,” the sources told PTI.
Currently Bharat Biotech’s Covaxin, Serum Institute’s Covishield and Covovax, Russian Sputnik V and Biological E Ltd’s Corbevax are listed in the CoWIN portal.
The vaccine maker, on September 6, announced that its iNCOVACC (BBV154), the world’s first intranasal COVID-19 vaccine has received approval from the Drugs Controller General of India under Restricted Use in Emergency Situation for ages 18 and above.
“There have been no requests for procurement from state or central governments,” sources further said.
The city-based vaccine maker also plans to export iNCOVACC to other countries once it gets approvals from the respective nations, sources added.
iNCOVACC (BBV154) has also received approval from the Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for ages 18 and above in India, for heterologous booster doses.
The vaccine was developed in partnership with Washington University, St Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated it in pre-clinical studies for efficacy.
The vaccine candidate underwent Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops.
Phase-III trials were conducted for safety, and immunogenicity in approximately 3,100 subjects, at 14 trial sites across India.
Also Read: Alembic Pharma receives EIR for Gujarat unit and approval for skin infection cream from USFDA
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Telangana Lok Sabha elections 2024: Asaduddin Owaisi to Bandi Sanjay Kumar, a look at key candidates
May 11, 2024 3:32 PM
Lok Sabha elections 2024: Hyderabad to Kadapa, key seats in fourth phase
May 11, 2024 2:54 PM
Telangana Lok Sabha elections 2024: List of BRS candidates
May 11, 2024 1:55 PM